Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 72
- Registration Number
- NCT00215644
- Locations
- 🇬🇧
Research Site, Portsmouth, United Kingdom
Patients Preference for Oral or i.v. Therapy
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2005-09-21
- Lead Sponsor
- Odense University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00212589
- Locations
- 🇩🇰
Department of Oncology, Esbjerg Hospital, Esbjerg, Denmark
🇩🇰Department of Oncology, Odense University Hospital, Odense, Denmark
🇩🇰Department of Oncology, Sonderborg Hospital, Sonderborg, Denmark
Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2015-03-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 51
- Registration Number
- NCT00209092
- Locations
- 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸Augusta Oncology Associates, PC 3696 Wheeler Road, Augusta, Georgia, United States
🇺🇸Emory Crawford Long Hospital, Atlanta, Georgia, United States
Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 25
- Registration Number
- NCT00207129
- Locations
- 🇺🇸
Local Institution, San Antonio, Texas, United States
Mono Efficacy of Capecitabine (MoniCa)
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-10-06
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 200
- Registration Number
- NCT00196820
- Locations
- 🇩🇪
J. W. Goethe Universität, Frauenklinik, Frankfurt am Main, Hessen, Germany
Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-09-23
- Target Recruit Count
- 57
- Registration Number
- NCT00201734
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Tony Bekaii-Saab
- Target Recruit Count
- 29
- Registration Number
- NCT00201825
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193102
Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00193609
- Locations
- 🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸Greenview Regional Hospital, Bowling Green, Kentucky, United States
🇺🇸Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States
Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-05-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT00191438
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nottingham City, Nottinghamshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.